Neuron23
Latest round
- Series D
Last raised
- Jun 2025
Total raised
- $310M
Investors
- 10
About Neuron23
Founded in 2018 and headquartered in San Francisco, US, Neuron23, Inc. is a biotechnology company dedicated to developing precision medicines using advanced data science and genetic insights to combat severe diseases, specializes in precision medicine and innovative drug discovery. In June 2025, Neuron23, Inc.Neuron23 is focused on developing precision medicines that harness the synergy of cutting-edge data science and human genetics to address debilitating diseases. Employing an innovative AI-based drug discovery model, they aim to identify novel molecular targets leading to effective treatments tailored to individual patient needs.S. market. Neuron23 generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and research institutions. Their business structure is primarily B2B, focusing on licensing agreements and research partnerships that share development costs and risks. plans to invest in its lead programs targeting LRRK2 and TYK2 to address Parkinson's disease and systemic inflammatory conditions. The company aims to expand its product offerings and may target global markets as their solutions mature.
Who invested in Neuron23
10 investors across 4 rounds
See all investors in Neuron23
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neuron23
Who invested in Neuron23?
Neuron23 has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neuron23 raised?
Neuron23 has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Neuron23 last raise money?
Neuron23's most recent round on record is a Series D, in Jun 2025.
What does Neuron23 do?
Founded in 2018 and headquartered in San Francisco, US, Neuron23, Inc.
Where is Neuron23 headquartered?
Neuron23 is headquartered in South San Francisco, US.
Which VCs invest in companies like Neuron23?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Neuron23's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Neuron23? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.